Belapectin

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Belapectin (also known as GR-MD-02) is a galectin-3 inhibitor developed by Galectin Therapeutics for the treatment of non-alcoholic steatohepatitis. In a phase 2b/3 trial belapectin at 2 mg/kg/LBW reduces varices development in MASH cirrhosis with portal hypertension.

Belapectin (also known as GR-MD-02) is a galectin-3 inhibitor developed by Galectin Therapeutics for the treatment of non-alcoholic steatohepatitis. In a phase 2b/3 trial belapectin at 2 mg/kg/LBW reduces varices development in MASH cirrhosis with portal hypertension.

References

Text derived from https://en.wikipedia.org/w/index.php?oldid=1303594802 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

2 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.